Immune checkpoint blockade therapy is changing oncology by improving the outcome of patients with advanced malignancies. Our research has revealed the genetic features of tumors present in patients who initiate a successful antitumor immune response and derive clinical benefit from immune checkpoint blockade therapy versus non-responders.
Keywords: CTLA-4; PD-1; biomarkers; cancer; genomics; immunomonitoring; immunotherapy; mutation; new targets.